Spots Global Cancer Trial Database for epacadostat
Every month we try and update this database with for epacadostat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | NCT01685255 | Ovarian Cancer Genitourinary (... | Epacadostat tamoxifen | 18 Years - | Incyte Corporation | |
| A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | NCT03414229 | Sarcoma | Epacadostat Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | NCT03217669 | Advanced Solid ... Non-small Cell ... | Epacadostat sirolimus | 18 Years - | University of Kansas Medical Center | |
| A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | NCT03322566 | Lung Cancer | Pembrolizumab Epacadostat Platinum-based ... Placebo | 18 Years - | Incyte Corporation | |
| A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies | NCT03471286 | Solid Tumor | Epacadostat | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | NCT01961115 | Mucosal Melanom... Recurrent Melan... Recurrent Uveal... Stage IIIA Skin... Stage IIIA Uvea... Stage IIIB Skin... Stage IIIB Uvea... Stage IIIC Skin... Stage IIIC Uvea... Stage IV Skin M... Stage IV Uveal ... | Epacadostat MELITAC 12.1 Pe... | 18 Years - | Fred Hutchinson Cancer Center | |
| A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | NCT01604889 | Melanoma | Epacadostat Placebo ipilimumab ipilimumab | 18 Years - | Incyte Corporation | |
| INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | NCT03589651 | Unresectable or... | Retifanlimab Epacadostat INCB050465 | 18 Years - | Incyte Corporation | |
| Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | NCT03358472 | Head and Neck C... | Pembrolizumab Epacadostat Cetuximab Cisplatin Carboplatin 5-Fluorouracil | 18 Years - | Incyte Corporation | |
| Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy | NCT03463161 | Head and Neck S... Head and Neck C... | Pembrolizumab Epacadostat | 18 Years - | University of Chicago | |
| A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | NCT03414229 | Sarcoma | Epacadostat Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | NCT03592407 | Esophageal Squa... Esophageal Aden... Gastroesophagea... | Epacadostat Laboratory Biom... Pembrolizumab Pharmacodynamic... | 18 Years - | City of Hope Medical Center | |
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | NCT04231864 | Epstein-Barr Vi... Metastatic Naso... Recurrent Nasop... Stage III Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... | Durvalumab Epacadostat | 18 Years - | University of California, San Francisco | |
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | NCT04586244 | Urothelial Carc... | retifanlimab epacadostat INCAGN02385 INCAGN02390 | 18 Years - | Incyte Corporation | |
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | NCT04586244 | Urothelial Carc... | retifanlimab epacadostat INCAGN02385 INCAGN02390 | 18 Years - | Incyte Corporation | |
| A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy | NCT03238638 | Head and Neck C... | Pembrolizumab epacadostat | 18 Years - | University of Chicago | |
| A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy | NCT03238638 | Head and Neck C... | Pembrolizumab epacadostat | 18 Years - | University of Chicago | |
| Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy | NCT03463161 | Head and Neck S... Head and Neck C... | Pembrolizumab Epacadostat | 18 Years - | University of Chicago | |
| Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | NCT03322540 | Lung Cancer | Pembrolizumab Epacadostat Placebo | 18 Years - | Incyte Corporation | |
| A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | NCT03361228 | Solid Tumors | INCB001158 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study | NCT03832673 | Muscle-invasive... | Pembrolizumab Epacadostat | 18 Years - 99 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat | NCT03823131 | Metastatic Head... Recurrent Head ... Unresectable He... | ImmunoPulse Epacadostat Pembrolizumab CORVax Tavokinogene te... | 18 Years - | University of California, San Francisco | |
| Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors | NCT02559492 | Solid Tumors | Itacitinib Epacadostat Itacitinib INCB050465 | 18 Years - | Incyte Corporation | |
| ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer | NCT03402880 | Extensive Stage... | Pembrolizumab Epacadostat Laboratory Biom... | 18 Years - | City of Hope Medical Center | |
| Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) | NCT03361865 | UC (Urothelial ... | Pembrolizumab Epacadostat Placebo | 18 Years - | Incyte Corporation | |
| A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | NCT03347123 | Solid Tumors | Epacadostat Nivolumab Ipilimumab Lirilumab | 18 Years - | Incyte Corporation | |
| A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110) | NCT02298153 | NSCLC (Non-smal... UC (Urothelial ... | atezolizumab epacadostat | 18 Years - | Incyte Corporation | |
| Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors | NCT02559492 | Solid Tumors | Itacitinib Epacadostat Itacitinib INCB050465 | 18 Years - | Incyte Corporation | |
| Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer | NCT03182894 | Metastatic Colo... | Epacadostat (IN... | 18 Years - | University of Pittsburgh | |
| Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | NCT03348904 | Lung Cancer | Nivolumab Epacadostat Placebo Carboplatin Cisplatin Gemcitabine Paclitaxel Pemetrexed | 18 Years - | Incyte Corporation | |
| Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | NCT03348904 | Lung Cancer | Nivolumab Epacadostat Placebo Carboplatin Cisplatin Gemcitabine Paclitaxel Pemetrexed | 18 Years - | Incyte Corporation | |
| A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies | NCT03471286 | Solid Tumor | Epacadostat | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | NCT03432676 | ATM Gene Mutati... Deleterious BRC... Deleterious BRC... Homologous Reco... Pancreatic Duct... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... | Epacadostat Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | NCT03358472 | Head and Neck C... | Pembrolizumab Epacadostat Cetuximab Cisplatin Carboplatin 5-Fluorouracil | 18 Years - | Incyte Corporation | |
| Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | NCT03348904 | Lung Cancer | Nivolumab Epacadostat Placebo Carboplatin Cisplatin Gemcitabine Paclitaxel Pemetrexed | 18 Years - | Incyte Corporation | |
| Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02042430 | Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Epacadostat Laboratory Biom... Therapeutic Con... | 19 Years - | National Cancer Institute (NCI) | |
| A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | NCT03414229 | Sarcoma | Epacadostat Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | NCT03358472 | Head and Neck C... | Pembrolizumab Epacadostat Cetuximab Cisplatin Carboplatin 5-Fluorouracil | 18 Years - | Incyte Corporation | |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | NCT02327078 | B-cell Malignan... Colorectal Canc... Head and Neck C... Lung Cancer Lymphoma Melanoma Ovarian Cancer Glioblastoma | Nivolumab Epacadostat Chemotherapy | 18 Years - | Incyte Corporation | |
| Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma | NCT03374488 | UC (Urothelial ... | Pembrolizumab Epacadostat Placebo | 18 Years - | Incyte Corporation | |
| Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | NCT03217669 | Advanced Solid ... Non-small Cell ... | Epacadostat sirolimus | 18 Years - | University of Kansas Medical Center | |
| Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | NCT03322540 | Lung Cancer | Pembrolizumab Epacadostat Placebo | 18 Years - | Incyte Corporation | |
| Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer | NCT03006302 | Metastatic Panc... | Epacadostat Pembrolizumab CRS-207 CY GVAX | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | NCT03358472 | Head and Neck C... | Pembrolizumab Epacadostat Cetuximab Cisplatin Carboplatin 5-Fluorouracil | 18 Years - | Incyte Corporation | |
| A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | NCT01685255 | Ovarian Cancer Genitourinary (... | Epacadostat tamoxifen | 18 Years - | Incyte Corporation | |
| A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | NCT01604889 | Melanoma | Epacadostat Placebo ipilimumab ipilimumab | 18 Years - | Incyte Corporation | |
| Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | NCT03260894 | Renal Cell Carc... | Pembrolizumab Epacadostat Sunitinib Pazopanib | 18 Years - | Incyte Corporation | |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | NCT03277352 | Advanced Malign... Metastatic Canc... | INCAGN01876 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | NCT03260894 | Renal Cell Carc... | Pembrolizumab Epacadostat Sunitinib Pazopanib | 18 Years - | Incyte Corporation | |
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | NCT04231864 | Epstein-Barr Vi... Metastatic Naso... Recurrent Nasop... Stage III Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... | Durvalumab Epacadostat | 18 Years - | University of California, San Francisco | |
| Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | NCT03342352 | Head and Neck C... | Nivolumab Epacadostat Placebo Carboplatin Cisplatin Cetuximab 5-Fluorouracil | 18 Years - | Incyte Corporation | |
| Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | NCT03325465 | Squamous Cell C... | Pembrolizumab Epacadostat | 18 Years - | University of Chicago | |
| Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer | NCT03182894 | Metastatic Colo... | Epacadostat (IN... | 18 Years - | University of Pittsburgh | |
| Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer | NCT02575807 | Platinum-resist... Platinum-resist... Platinum-resist... | CRS-207 Epacadostat Pembrolizumab | 18 Years - | Aduro Biotech, Inc. | |
| Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | NCT02364076 | Thymic Carcinom... Thymus Neoplasm... Thymus Cancer | Pembrolizumab Epacadostat | 18 Years - | Georgetown University | |
| Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | NCT04463771 | Endometrial Can... | retifanlimab epacadostat pemigatinib INCAGN02385 INCAGN02390 | 18 Years - | Incyte Corporation | |
| Epacadostat and Pembrolizumab in Patients With GIST | NCT03291054 | Gastrointestina... | Pembrolizumab Epacadostat | 18 Years - | Columbia University | |
| Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | NCT02959437 | Solid Tumors Advanced Malign... Metastatic Canc... | Azacitidine Pembrolizumab Epacadostat INCB057643 Pembrolizumab Epacadostat INCB059872 | 18 Years - | Incyte Corporation | |
| Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | NCT03322540 | Lung Cancer | Pembrolizumab Epacadostat Placebo | 18 Years - | Incyte Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
